
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **GATA3**: A transcription factor critical for the development and differentiation of various tissues, including the mammary gland. It is often associated with luminal epithelial cells in the breast.<br>- **XBP1**: A transcription factor involved in the unfolded protein response and is known to play a role in the differentiation of plasma cells and secretory cells.<br>- **CCND1 (Cyclin D1)**: Involved in cell cycle regulation and is frequently overexpressed in breast cancer, particularly in luminal subtypes.<br>- **ERBB3 (HER3)**: A member of the epidermal growth factor receptor (EGFR) family, often implicated in breast cancer signaling pathways.<br>- **CD24**: A cell surface protein often used as a marker for epithelial and cancer stem cells in breast tissue.<br>- **KRT18 (Keratin 18)**: An intermediate filament protein typically expressed in epithelial cells, including luminal epithelial cells of the breast.<br><br>### Step 2: List the Key Cell Type Markers<br>- **SCGB2A2 (Mammaglobin)**: A marker highly specific to breast tissue, particularly luminal epithelial cells.<br>- **ANRKD30A**: Known to be expressed in breast tissue, often associated with luminal epithelial cells.<br>- **TFF3 (Trefoil Factor 3)**: Expressed in mucosal epithelial cells and often associated with luminal epithelial cells in the breast.<br>- **MLPH (Melanophilin)**: Involved in melanosome transport but also expressed in certain epithelial cells.<br>- **DSP (Desmoplakin)**: A component of desmosomes, which are important for cell-cell adhesion in epithelial tissues.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on breast cancer and scRNA-seq, the markers SCGB2A2, GATA3, and KRT18 are strongly associated with luminal epithelial cells in the breast. These markers are frequently used to identify luminal subtypes in breast cancer studies.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of markers such as SCGB2A2, GATA3, KRT18, and ERBB3, the most probable general cell type is **luminal epithelial cells**. These cells are a major component of the breast tissue and are often implicated in breast cancer, particularly in luminal subtypes.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Luminal A Subtype**: Characterized by high expression of hormone receptors and low proliferation rates. Markers like GATA3 and CCND1 support this subtype.<br>2. **Luminal B Subtype**: Similar to Luminal A but with higher proliferation rates and often more aggressive. The presence of ERBB3 and CCND1 can also indicate this subtype.<br>3. **Normal Luminal Epithelial Cells**: These are non-cancerous luminal cells that express markers like SCGB2A2 and KRT18.<br><br>The most likely subtype based on the markers is the **Luminal A Subtype**, given the expression of GATA3, SCGB2A2, and other luminal markers.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of luminal epithelial cells. The expression of key markers such as SCGB2A2, GATA3, and KRT18 strongly indicates a luminal origin. Among the luminal subtypes, the Luminal A subtype is the most probable due to the presence of markers associated with hormone receptor positivity and lower proliferation rates.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    To validate the annotation result, let's follow the outlined steps:<br><br>### Step 1: Marker Consistency<br>- **Markers in the Provided List**: The key functional markers and cell type markers mentioned in the annotation (GATA3, XBP1, CCND1, ERBB3, CD24, KRT18, SCGB2A2, ANRKD30A, TFF3, MLPH, DSP) are all present in the provided marker list.<br>- **Consistency with Identified Cell Type**: The markers SCGB2A2, GATA3, and KRT18 are strongly associated with luminal epithelial cells, which is consistent with the annotation of the cell type as luminal epithelial cells. The presence of ERBB3 and CCND1 supports the identification of luminal subtypes, particularly Luminal A and B.<br><br>### Step 2: Mixed Cell Type Consideration<br>- **Potential Mixed Populations**: The annotation does not strongly suggest the presence of multiple distinct cell types. The markers used are consistently associated with luminal epithelial cells and their subtypes. There is no strong evidence of mixed cell types based on the high-ranking markers provided.<br><br>### Conclusion<br>The annotation result is consistent with the provided marker list and the identified cell type. The markers used are appropriate for identifying luminal epithelial cells and their subtypes in breast tissue.<br><br>Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">luminal epithelial cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Luminal A Subtype</li><li>Luminal B Subtype</li><li>Normal Luminal Epithelial Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the markers associated with luminal epithelial cells in breast cancer. The analysis correctly identifies key markers such as GATA3, SCGB2A2, and KRT18, which are well-documented in the literature as being indicative of luminal epithelial cells. The annotation also appropriately considers the presence of ERBB3 and CCND1, which are relevant to distinguishing between luminal subtypes, particularly Luminal A and B.<br><br>The annotation process is thorough, with a clear step-by-step approach that includes listing key functional and cell type markers, cross-referencing with known databases, and determining the most probable cell types and subtypes. This methodical approach ensures that the annotation is grounded in scientific evidence and provides a comprehensive view of the cell populations present.<br><br>One strength of the annotation is its balanced consideration of multiple markers, rather than over-focusing on a single one. This is evident in the inclusion of a variety of markers that collectively support the identification of luminal epithelial cells and their subtypes. The annotation also successfully captures the general picture of the cell populations, as it considers both the main cell type and potential subtypes.<br><br>However, there are a few areas for improvement. While the annotation does not suggest the presence of mixed cell types, it could have explored this possibility further, given the complexity of breast cancer tissues. Additionally, the annotation could have placed more emphasis on the rank of the markers, as markers appearing earlier in the list may hold more significance.<br><br>Overall, the annotation is scientifically accurate, well-balanced, and provides a comprehensive view of the cell types present. There are no obvious misclassifications or oversights, and the analysis is consistent with the provided marker list.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    